The agency said Shkreli, 39, hadn’t complied with its requests to submit documents and participate in an interview on his new company Druglike Inc., which “purports to revolutionize early-stage drug discovery through a decentralized computing network.”
“Martin Shkreli’s failure to comply with the court’s order demonstrates a clear disregard for the law,” Holly Vedova, director of the FTC’s Bureau of Competition, said in a statement. “The FTC will not hesitate to deploy the full scope of its authorities to enable a comprehensive investigation into any potential misconduct.”
Last February, Shkreli was permanently barred from “directly or indirectly participating in any manner in the pharmaceutical industry” — a ban imposed after he was determined to have run an “illegal anticompetitive scheme” to maintain a monopoly on the life-saving drug Daraprim.
In addition to the ban, Shkreli was found liable for $64.6 million in penalties related to his effort to stifle rivals. The FTC said Shkreli has yet to repay any of the money.
The FTC alleged that Shkreli has “disregarded the agency’s repeated requests” for information meant to determine whether he was violating the court-ordered ban.
An attorney for Shkreli, Brianne Murphy, said Druglike is a software company rather than a pharmaceutical company and said the legal team is aiming for a swift resolution to the dispute.
“We think that this is a misunderstanding with the FTC,” Murphy said.
Shkreli became a reviled figure in 2015 after he raised the price of a single pill of Draraprim from $13.50 to $750 while serving as CEO of Turing Pharmaceuticals. He was later sentenced to seven years in prison after being convicted on charges of defrauding investors in two hedge funds he had previously led.